^
Association details:
| Biomarker: | AKT1 mutation + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Truqap (capivasertib) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer
Published date:
06/20/2024
Excerpt:
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.
Secondary therapy:
fulvestrant
